Avastin, Eylea, Lucentis sustain improved visual acuity gains in DME in DRCR.net protocol

Intravitreal Avastin, Eylea and Lucentis similarly sustained visual acuity gains in patients with visually significant center-involved diabetic macular edema, according to a study.However, in eyes with worse baseline visual acuity, Eylea (aflibercept, Regeneron) improved vision significantly more than Avastin (bevacizumab, Genentech) and Lucentis (ranibizumab, Genentech).